3-Diarylmethylenes Modulating PP2A to Overcome Cancer Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers such as prostate and triple-negative breast cancer are inadequate, particularly for castration-resistant prostate cancer and chemotherapy-resistant breast cancer, as they often develop resistance and lack effective therapeutic targets.
Innovation Solution
Development of 3-diarylmethyl cycloamine urea analogs that modulate PP2A activity to induce FOXO1 and FOXO3 transcription factor translocation, deactivating pro-growth kinases like phospho-ERK and phospho-AKT, thereby exhibiting anti-proliferative effects and restoring sensitivity to chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments (androgen ablation, chemotherapy) are used, then tumor regression and symptomatic improvement are achieved, but tumors inevitably develop resistance and progress
Solution Approach 1:
The patent changes the molecular target parameter from traditional androgen receptor or chemotherapy targets to PP2A phosphatase activity. By modulating PP2A activity, the compound induces FOXO transcription factor translocation and deactivates pro-growth kinases, creating a new therapeutic parameter that avoids resistance mechanisms of conventional treatments.
Solution Approach 2:
The patent introduces PP2A phosphatase as an intermediary target between the compound and the cancer cells. The compound modulates PP2A activity, which then mediates the downstream effects of inducing FOXO translocation and deactivating kinases like ERK and AKT, leading to anti-proliferative effects.
2Productivity
If androgen ablation therapy is used for metastatic prostate cancer, then tumor growth is slowed at castrate testosterone levels, but tumors ultimately develop resistance
Solution Approach 1:
The patent extracts the therapeutic mechanism from androgen dependency by targeting PP2A phosphatase activity independently of testosterone levels. This allows effective treatment in castration-resistant prostate cancer where traditional androgen ablation fails, as the mechanism no longer depends on androgen signaling.
Solution Approach 2:
Instead of reducing androgen levels to control cancer growth, the patent inverts the approach by increasing PP2A activity to deactivate pro-growth signaling pathways. This inverse strategy targets the downstream effectors of androgen signaling, rendering the cancer cells resistant to androgen-dependent therapies.
3Ease of manufacture
If chemotherapy is used for triple-negative breast cancer, then cancer treatment is provided, but chemotherapy resistance develops
Solution Approach 1:
The patent uses PP2A phosphatase as an intermediary to restore chemotherapy sensitivity. By modulating PP2A activity, the compound deactivates pro-growth kinases that promote chemotherapy resistance, thereby making tumor cells more susceptible to chemotherapy treatment.
Solution Approach 2:
The patent performs preliminary action by pre-modulating PP2A activity and inducing FOXO translocation before chemotherapy administration. This preliminary modulation of cellular signaling pathways prepares the tumor cells to be more sensitive to subsequent chemotherapy treatment, reversing resistance mechanisms.
Data Source
AI summary
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.